Skip to main content

Table 4 Univariate and multivariate analyses of overall survival in patients with hormone receptor-positive/HER2-negative primary breast cancer

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

   Univariate Multivariate
   Total Hazard (95% CI) P-value Hazard (95%CI) P-value
   (n=142) ratio    ratio   
Ki67-p53 Low Ki67 LI and Negative p53 88 1    1   
  High Ki67 LI and/or Positive p53 54 8.8 1.9-40.4 0.0049 7.9 1.7-36.7 0.0081
FOXA1 Low 20 1      
  High 119 0.49 0.06-3.9 0.50    
GATA3 Negative 30 1      
  Positive 112 1.1 0.31-4.3 0.84    
Basal phenotype marker Negative 9 1      
(CK5/6, CK14, EGFR) Positive 133 1.2 0.15-9.3 0.86    
P-cadherin Low 90 1      
  High 52 1.8 0.57-5.5 0.32    
Tumor size <5.0cm 17 1      
  5.0cm 122 3.4 0.90-12.8 0.071    
Lymph-node metastasis (−) 80 1      
  (+) 59 3.9 1.02-14.7 0.045    
Nuclear grade 1, 2 111 1      
  3 31 3.8 1.2-11.9 0.0020    
Chemotherapy No 93 1      
  Yes 49 2.0 0.65-6.3 0.22    
  1. Abbreviation: 95%CI 95% confidence interval, LI labeling index.